Rights and permissions
About this article
Cite this article
Thompson, H. US National Cancer Institute's new Ras project targets an old foe. Nat Med 19, 949–950 (2013). https://doi.org/10.1038/nm0813-949
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm0813-949
- Springer Nature America, Inc.
This article is cited by
-
Peptidomimetics designed to bind to RAS effector domain are promising cancer therapeutic compounds
Scientific Reports (2022)
-
EPHA2 feedback activation limits the response to PDEδ inhibition in KRAS-dependent cancer cells
Acta Pharmacologica Sinica (2020)
-
Comparison of Native Aspirates and Cytological Smears Obtained by EUS-Guided Biopsies for Effective DNA/RNA Marker Testing in Pancreatic Cancer
Pathology & Oncology Research (2020)
-
A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer
Scientific Reports (2019)
-
Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
Nature Communications (2016)